Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

De Grève, J; Teugels, E; Geers, C; Decoster, L; Galdermans, D; De Mey, J; Everaert, H; Umelo, I; In't Veld, P; Schallier, D

De Grève, J; Teugels, E; Geers, C; Decoster, L; Galdermans, D; De Mey, J; Everaert, H; Umelo, I; In't Veld, P; Schallier, D.

Affiliation

De Grève J; Oncologisch Centrum UZ Brussel, Brussels, Belgium. Jacques.degreve@uzbrussel.be

Lung Cancer ; 76(1): 123-7, 2012 Apr.

Article in En | MEDLINE | ID: mdl-22325357

Subject(s)

Adenocarcinoma/genetics; Lung Neoplasms/genetics; Mutation/genetics; Quinazolines/therapeutic use; Receptor, ErbB-2/genetics; Adenocarcinoma/diagnosis; Adenocarcinoma/drug therapy; Afatinib; Aged; Amino Acid Sequence; ErbB Receptors/genetics; Female; Humans; Lung Neoplasms/diagnosis; Lung Neoplasms/drug therapy; Male; Middle Aged; Molecular Sequence Data; Prognosis; Protein Kinases/genetics; Receptor, ErbB-2/antagonists & inhibitors; Sequence Homology, Amino Acid

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Adenocarcinoma / Receptor, ErbB-2 / Lung Neoplasms / Mutation Type of study: Diagnostic_studies / Prognostic_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Lung Cancer Journal subject: NEOPLASIAS Year: 2012 Document type: Article Affiliation country: Belgium

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google